相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2021)
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar et al.
LANCET ONCOLOGY (2021)
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
Connie L. Batlevi et al.
BLOOD CANCER JOURNAL (2020)
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Antonio Cuneo et al.
HEMATOLOGICAL ONCOLOGY (2019)
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies
Pier Luigi Zinzani et al.
BLOOD (2019)
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia
Benjamin L. Lampson et al.
BLOOD ADVANCES (2019)
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A. Burris et al.
LANCET ONCOLOGY (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date
Till Seiler et al.
DRUGS (2016)
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in CombinationWith Erlotinib in Patients With Solid Tumors
Jean-Charles Soria et al.
ONCOLOGIST (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Naifa L. Busaidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
分享论文
